Hematologic Malignancy
Mature B-Cell Non-Hodgkin Lymphoma
CI-CAN-00003259Explore in graph →
Hematologic792 active trials17 approved drugs43 evidence items
- NCIt
- C7056
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003259Explore in graph →
Clinical trials
2,506 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (393)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00439231 | Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | completed | Phase 2 | 33 | Georg Aue, M.D.NIH | 1 | Jan 13, 2014 | clinicaltrials |
| NCT01040871 | Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma | completed | Phase 2 | 164 | Millennium Pharmaceuticals, Inc.INDUSTRY |
| 1 |
| Jan 13, 2014 |
| clinicaltrials |
| NCT00769288 | FAU in Treating Patients With Advanced Solid Tumors or Lymphoma | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2014 | clinicaltrials |
| NCT00656812 | Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma | completed | Phase 2 | 40 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Dec 24, 2013 | clinicaltrials |
| NCT00373906 | Velcade in MALT Lymphoma Patients | completed | Phase 2 | 16 | Medical University of ViennaOTHER | 0 | Nov 27, 2013 | clinicaltrials |
| NCT01164267 | Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL) | completed | Phase 2 | 30 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 3 | Nov 25, 2013 | clinicaltrials |
| NCT01361191 | Early Treatment Stratification Based on PET Scan Response to Chemotherapy in Patients With Diffuse Large B-cell Lymphoma(R-MEGACHOP) | completed | Phase 2 | 71 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Oct 30, 2013 | clinicaltrials |
| NCT00949741 | Observational Study for the Cytofluorimetric Analysis of Cerebrospinal Fluid in Non-Hodgkin's Lymphoma Patients(CFM) | completed | — | 175 | Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle LeucemieOTHER | 1 | Oct 22, 2013 | clinicaltrials |
| NCT01205737 | A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects | completed | Phase 1 | 186 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 10 | Oct 22, 2013 | clinicaltrials |
| NCT00068315 | Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00079378 | Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 1 | 84 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00293345 | 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00575406 | Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell Lymphoma(NHL-14) | completed | Phase 2 | 94 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Aug 30, 2013 | clinicaltrials |
| NCT00026182 | Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 99 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2013 | clinicaltrials |
| NCT01118689 | Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia | completed | Phase 1 | 39 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2013 | clinicaltrials |
| NCT00842595 | Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas | completed | Phase 2 | 50 | French Innovative Leukemia OrganisationOTHER | 1 | Jul 24, 2013 | clinicaltrials |
| NCT00089154 | Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2013 | clinicaltrials |
| NCT01118845 | Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma | completed | Phase 2 | 63 | SymBio PharmaceuticalsINDUSTRY | 2 | Jul 4, 2013 | clinicaltrials |
| NCT00807677 | A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies | completed | Phase 1 | 31 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00994500 | Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00010192 | Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2013 | clinicaltrials |
| NCT00101270 | Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00017472 | Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemia | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00058227 | Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00062244 | Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia | completed | Phase 1 / Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00109824 | Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00873457 | Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | completed | Phase 2 | 16 | Daphne FriedmanOTHER | 1 | May 27, 2013 | clinicaltrials |
| NCT00054483 | Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction | completed | Phase 1 | 69 | National Cancer Institute (NCI)NIH | 1 | May 16, 2013 | clinicaltrials |
| NCT00348985 | PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 55 | National Cancer Institute (NCI)NIH | 1 | May 3, 2013 | clinicaltrials |
| NCT00715208 | Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma | completed | Phase 2 | 55 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Apr 29, 2013 | clinicaltrials |
| NCT00060372 | Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer | completed | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Mar 27, 2013 | clinicaltrials |
| NCT01148108 | Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma | completed | Phase 2 | 14 | TelikINDUSTRY | 1 | Mar 15, 2013 | clinicaltrials |
| NCT00412243 | Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients | completed | Phase 1 / Phase 2 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 12, 2013 | clinicaltrials |
| NCT00002649 | Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma | completed | Phase 3 | 206 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00003204 | Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma | completed | Phase 3 | 515 | National Cancer Institute (NCI)NIH | 1 | Feb 27, 2013 | clinicaltrials |
| NCT00005811 | Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment | completed | Phase 2 | 77 | National Cancer Institute (NCI)NIH | 1 | Feb 21, 2013 | clinicaltrials |
| NCT00004241 | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00025415 | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00278382 | Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma | completed | Phase 2 | 33 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00016094 | S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 29, 2013 | clinicaltrials |
| NCT00064246 | Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder | completed | Phase 1 / Phase 2 | 28 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00089271 | 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00003970 | Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00077155 | Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00086944 | Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00098891 | MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00006473 | Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 72 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00777738 | Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia(WM2) | completed | Phase 2 | 34 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 18, 2013 | clinicaltrials |
| NCT01345357 | Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma | completed | Phase 1 | 24 | CephalonINDUSTRY | 2 | Jan 18, 2013 | clinicaltrials |
| NCT00363272 | Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Jan 13, 2014source: clinicaltrials